Synthetic Design Lab — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Synthetic Design Lab is a private, preclinical-stage biotech pioneering a novel Antibody-Drug Conjugate (ADC) platform designed to deliver a 10x greater payload to target cells. Led by a seasoned team with deep experience in ADC development, protein engineering, and clinical translation from companies like Genentech and IGM Biosciences, the company is targeting a range of validated oncology antigens. SDL's core value proposition is its SYNTHBODY™ platform, which integrates biology and biophysics to optimize targeted delivery, potentially unlocking new efficacy and safety paradigms in the competitive ADC landscape.

Oncology

Technology Platform

SYNTHBODY™, a next-generation ADC platform engineered to deliver payloads to target cells at ≥10x the level of current ADCs by integrating biology, biophysics, and engineering for optimized targeted delivery.

Opportunities

The global ADC market is large and rapidly growing, providing a substantial addressable market.

SDL's platform, if validated, could create best-in-class therapies in established markets (e.g., HER2, TROP2) and enable effective targeting of new antigens, potentially through future strategic partnerships with large pharma.

Risk Factors

The core risk is the preclinical claim of 10x greater payload delivery failing to translate into a superior therapeutic index in human trials.

The company also faces intense competition from large, well-funded players in the ADC space and is dependent on venture financing to reach clinical milestones.

Competitive Landscape

SDL operates in the highly competitive ADC field, competing directly with leaders like AstraZeneca/Daiichi Sankyo (Enhertu), Gilead (Trodelvy), and Pfizer, as well as numerous biotechs. Its differentiation hinges solely on proving its SYNTHBODY™ platform delivers a clinically meaningful advantage in efficacy and/or safety over existing technologies.

More companies in Antibody-Drug Conjugates →More companies in United States →